Beta Bionics, Inc. (BBNX)
| Market Cap | 556.11M |
| Revenue (ttm) | 100.25M |
| Net Income (ttm) | -73.20M |
| Shares Out | 44.38M |
| EPS (ttm) | -1.81 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,140,990 |
| Open | 12.39 |
| Previous Close | 12.63 |
| Day's Range | 12.06 - 12.67 |
| 52-Week Range | 8.89 - 32.71 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 26.73 (+113.33%) |
| Earnings Date | Feb 17, 2026 |
About BBNX
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which co... [Read more]
Financial Performance
In 2025, Beta Bionics's revenue was $100.25 million, an increase of 53.94% compared to the previous year's $65.12 million. Losses were -$73.20 million, 33.7% more than in 2024.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for BBNX stock is "Strong Buy." The 12-month stock price target is $26.73, which is an increase of 113.33% from the latest price.
News
BBNX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options ...
Beta Bionics to Present at the TD Cowen 46th Annual Health Care Conference
IRVINE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management w...
Beta Bionics, Inc. (BBNX) Q4 2025 Earnings Call Transcript
Beta Bionics, Inc. (BBNX) Q4 2025 Earnings Call Transcript
INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options If you suff...
Beta Bionics Announces Fourth Quarter and Full Year 2025 Financial Results and Introduces Annual Guidance for Full Year 2026
IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial resu...
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options If you suf...
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options I...
SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses in Beta Bionics to Contact Him Directly to Discuss Their Options If you suff...
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options
BBNX Investors Have Opportunity to Join Beta Bionics, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Beta Bionics, Inc...
INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options If you suf...
Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Beta Bionics, Inc. (NASDAQ: BBNX)
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether Beta Bionics, Inc. (“Beta Bion...
Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
IRVINE, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to ...
Beta Bionics, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - BBNX
LOS ANGELES, Jan. 15, 2026 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Beta Bionics, Inc. ("Beta Bionics" or "the Company") (NASDAQ: BBNX) for...
Beta Bionics Key KPI Miss Targets, Analyst Flags Valuation Risks
Diabetes management solutions provider, Beta Bionics Inc. (NASDAQ: BBNX), on Thursday reported preliminary fourth-quarter 2025 results showing strong revenue growth, driven by rapid expansion in its P...
Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results and Key Metrics
IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its preliminary, u...
Beta Bionics to Pre-Announce Topline Fourth Quarter 2025 Financial Results the Week of January 5, 2026
IRVINE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) (the “Company”), a pioneering leader in the development of advanced diabetes management solutions, today announced t...
Beta Bionics Announces Participation at Upcoming Investor Conferences
IRVINE, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management w...
Beta Bionics, Inc. (BBNX) Q3 2025 Earnings Call Transcript
Beta Bionics, Inc. (NASDAQ:BBNX) Q3 2025 Earnings Call October 28, 2025 4:30 PM EDT Company Participants Blake Beber - Head of Investor Relations Sean Saint - President, CEO & Director Stephen Feider...
Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance
IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial resu...
Beta Bionics to Announce Third Quarter 2025 Financial Results on October 28, 2025
IRVINE, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to ...
Beta Bionics, Inc. (BBNX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Beta Bionics, Inc. (NASDAQ:BBNX) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 1:50 PM EDT Company Participants Stephen Feider - CFO, Treasurer & Secretary Sean Saint - Pr...
Beta Bionics: Guiding Conservative After All
Beta Bionics' iLet product is gaining traction, but management's conservative guidance has created uncertainty around future growth and competitiveness. Recent quarters showed strong revenue growth an...
Beta Bionics, Inc. (BBNX) Q2 2025 Earnings Call Transcript
Beta Bionics, Inc. (NASDAQ:BBNX) Q2 2025 Earnings Call July 29, 2025 4:30 PM ET Company Participants Blake Beber - Head of Investor Relations Sean T. Saint - President, CEO & Director Stephen H.
Beta Bionics Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Guidance
IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial resu...